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Background: We hypothesized that aging results in increased left ventricular (LV), atrial and kidney fibrosis after reperfused myocardial infarction 
(RMI) and therapy with the angiotensin II type 1 receptor (AT1R) blocker candesartan (CN) attenuates the fibrosis and remodeling.
Methods: We randomized 60 young (3 months) and 60 adult (12 months) Sprague-Dawley rats 24 h after RMI to 4 weeks of oral therapy with 
placebo or CN (30 mg/kg). We measured in vivo LV function and remodeling over 4 weeks, kidney function at 4 weeks, and ex vivo LV, left atrial (LA) 
and kidney volume/mass ratios, collagens and fibrosis, pertinent signaling pathways, and infarct-scar size at 4 weeks.
Results: Compared to sham groups, RMI-placebo resulted in larger infarct-scar areas (% risk), more in vivo LV dysfunction (systolic and 
diastolic) and remodeling (LV dilation, scar expansion and thinning) as well as more ex vivo LV, LA and kidney remodeling (fibrosis; volume/mass 
ratios; hydroxyproline; collagen types I and III, soluble and cross-linked insoluble) and greater increases in angiotensin II, inflammatory cytokine 
interleukin-6, tumor necrosis factor-_, transforming growth factor-`1 and Smad-2 in the older than young hearts (P<0.01-0.001). Compared to 
RMI-placebo, CN attenuated the aging-related increases in LV dysfunction as well as LV, LA and kidney fibrosis and remodeling. CN also attenuated 
aging-related increase in kidney dysfunction. 
Conclusions: The overall findings suggest that aging augments RMI-induced increases in LV dysfunction and remodeling, kidney dysfunction, as 
well as LV, LA and kidney fibrosis and remodeling, and the AT1R blocker CN attenuates these changes
